RecruitingPhase 1NCT05377996
A Study of XMT-1660 in Participants With Solid Tumors
A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors
Sponsor
Mersana Therapeutics
Enrollment
319 participants
Start Date
Aug 15, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
A Study of XMT-1660 in Solid Tumors
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing a new cancer drug called XMT-1660 — a type of antibody-drug conjugate, which is like a guided missile that targets cancer cells and delivers chemotherapy directly to them — in people with advanced or recurring solid tumors.
**You may be eligible if...**
- You have an advanced or recurrent solid tumor that has come back or progressed
- You are in good overall health (ECOG performance status 0 or 1)
- You have a tumor that can be measured or assessed by standard imaging
- You can provide a tumor tissue sample (either from a previous biopsy or a new one)
**You may NOT be eligible if...**
- You have untreated or active brain metastases that are not stable
- Your tumor tissue is not available and you cannot undergo a new biopsy
- Your overall health status is too poor to tolerate experimental treatment
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGXMT-1660
XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05377996
Related Trials
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT05640999108 locations
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693485 locations
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
NCT0689033864 locations
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
NCT055686805 locations
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT0646506931 locations